Log in


Advancing translational life sciences research and academic technology transfer

  • Home
  • Temple Treats First Patients in the U.S. in Clinical Trial of Novel Immunotherapy for Patients with COVID-19, Temple University Hospital

Temple Treats First Patients in the U.S. in Clinical Trial of Novel Immunotherapy for Patients with COVID-19, Temple University Hospital

9 Jul 2020 10:01 AM | Anonymous

Temple University Hospital has treated the first five patients in the United States as part of a Phase 1 clinical trial investigating a novel immunotherapy approach for patients with COVID-19. CPI-006, developed by Corvus Pharmaceuticals, Inc., has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer. Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, is the principal investigator at Temple.

<<FULL STORY>>

Contact Us

admin@biostrategypartners.org
717-514-0436

P.O. Box 83 Boiling Springs, PA 17007



Copyright 2017, BioStrategy Partners. All rights reserved.   
Powered by Wild Apricot Membership Software